Bridge Financial Statements From 2010 to 2024
| 288330 Stock | KRW 3,940 120.00 2.96% |
Check Bridge Biotherapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Bridge Biotherapeutics' main balance sheet or income statement drivers, such as , as well as many indicators such as . Bridge financial statements analysis is a perfect complement when working with Bridge Biotherapeutics Valuation or Volatility modules.
Bridge |
Bridge Biotherapeutics Company Revenue Analysis
Bridge Biotherapeutics' Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Current Bridge Biotherapeutics Revenue | 1.92 B |
Most of Bridge Biotherapeutics' fundamental indicators, such as Revenue, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Bridge Biotherapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
| Competition |
Based on the latest financial disclosure, Bridge Biotherapeutics reported 1.92 B of revenue. This is 74.77% lower than that of the Healthcare sector and significantly higher than that of the Biotechnology & Medical Research industry. The revenue for all Republic of Korea stocks is 79.61% higher than that of the company.
Bridge Biotherapeutics Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Bridge Biotherapeutics's current stock value. Our valuation model uses many indicators to compare Bridge Biotherapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Bridge Biotherapeutics competition to find correlations between indicators driving Bridge Biotherapeutics's intrinsic value. More Info.Bridge Biotherapeutics is rated below average in return on equity category among its peers. It is rated below average in current valuation category among its peers . Comparative valuation analysis is a catch-all model that can be used if you cannot value Bridge Biotherapeutics by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Bridge Biotherapeutics' Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.About Bridge Biotherapeutics Financial Statements
Bridge Biotherapeutics stakeholders use historical fundamental indicators, such as Bridge Biotherapeutics' revenue or net income, to determine how well the company is positioned to perform in the future. Although Bridge Biotherapeutics investors may analyze each financial statement separately, they are all interrelated. For example, changes in Bridge Biotherapeutics' assets and liabilities are reflected in the revenues and expenses on Bridge Biotherapeutics' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Bridge Biotherapeutics. Please read more on our technical analysis and fundamental analysis pages.
Bridge Biotherapeutics, Inc., a clinical stage biotech company, engages in the development of therapeutics for the treatment of ulcerative colitis, fibrotic diseases, and cancers worldwide. The company was founded in 2015 and is headquartered in Seongnam, Korea. BRIDGE BIOTHERAPEUTICS is traded on Korean Securities Dealers Automated Quotations in South Korea.
Pair Trading with Bridge Biotherapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Bridge Biotherapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Bridge Biotherapeutics will appreciate offsetting losses from the drop in the long position's value.Moving together with Bridge Stock
Moving against Bridge Stock
| 0.56 | 041510 | SM Entertainment | PairCorr |
| 0.56 | 032640 | LG Uplus | PairCorr |
| 0.54 | 035420 | Naver | PairCorr |
| 0.39 | 078160 | MEDIPOST | PairCorr |
| 0.36 | 011390 | Busan Industrial | PairCorr |
The ability to find closely correlated positions to Bridge Biotherapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Bridge Biotherapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Bridge Biotherapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Bridge Biotherapeutics to buy it.
The correlation of Bridge Biotherapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Bridge Biotherapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Bridge Biotherapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Bridge Biotherapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Other Information on Investing in Bridge Stock
Bridge Biotherapeutics financial ratios help investors to determine whether Bridge Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Bridge with respect to the benefits of owning Bridge Biotherapeutics security.